Objective To investigate the diagnostic status of pulmonary thromboembolism (PTE) for inpatients in Peking Union hospital Methods Inpatients diagnosed acute PTE from January 1999 to December 2002 were reviewed and divided by sex, age and risk factors Results Among 78 844 inpatients, 155 were diagnosed PTE during 4 year period, 73 of 27 100 in men (0 27%) vs 82 of 51 744(0 16%)in women, and 52 of 17 459 (0 30% ) in elderly patients(≥60 years) vs 103 of 61 385 (0 17% ) in non elderly patients(

The magnetic nanoparticle probe was prepared by specifically connecting the streptavidin-conjugated magnetic nanoparticles and the antibody of analyte via the strong streptavidin-biotin interaction. Based on the magnetic nanoparticle probes, the concentration of human chorionicgonadotropin (HCG) was detected and a new CL method for of hormone was further established. The performances of the magnetic nanoparticle probes were characterized by UV-Vis spectrometry, transmission electron microscopy and dynamic light scattering. The experimental conditions that affected the chemiluminescence were optimized. The optimal concentrations of luminal and H_2O_2 were 2×10~(-4) mol/L and 8×10~(-4) mol/L, respectively, and optimal pH was 13. Under the optimized experiment conditions, a linear response of chemiluminescence intensity to HCG concentration was obtained with a correlation coefficients of 0.9924. The linear range was from 0.5 to 250 μg/L and wider than the conventional ELISA method (5-200 μg/L). The relative standard deviation was 3.8%. Correlation analysis showed that there was significant correlation between the method of magnetic nanoparticle probes and ELISA in 34 clinical samples. The proposed method with characters of sensitive, effective, fast response and wide detection range provided good application prospect in analysis of other ultra-micro protein.

A highly sensitive magnetic enzymE-linked chemiluminescent immunoassay method was developed for the detection of human chorionic gonadotropin(HCG). The monoclonal antibody was covalently coupled on the surface of carboxylated magnetic beads to generate magnetic-biotargeting; Alkaline phosphatase(ALP) was utilized as a labeled reagent of another monoclonal antibody, whereas 3-(2-spimadamantane) 4-methoxy-4-(3-phosphoryloxy)phenyl-1,2-dioxetane(AMPPD) was utilized as the chemiluminescent substrate. Based on this concept, a highly sensitive chemiluminescent immunoassay method was established to test HCG. Then, several modifications were made to optimize the method, and the detection sensitivity and procedure were improved accordingly. The detection of the assay could be fulfilled within 60 min and the test result of HCG concentration was linear over the range of 0.15 150 IU/L with good relativity(r=0.960). The relative standard deviation(RSD) were below 5% and the sensitivity of this method was 0.15 IU/L. The proposed method with wide linear range, simple operation and fast detection showed good prospect in practical application on-site.

Deep brain stimulation(DBS),including optical stimulation and electrical stimulation,has been demonstrated considerable value in exploring pathological brain activity and developing treatments for neural disorders.Advances in DBS microsystems based on implantable microelectrode array(MEA)probes have opened up new opportunities for closed-loop DBS(CL-DBS)in situ.This technology can be used to detect damaged brain circuits and test the therapeutic potential for modulating the output of these circuits in a variety of diseases simultaneously.Despite the success and rapid utilization of MEA probe-based CL-DBS microsystems,key challenges,including excessive wired communication,need to be urgently resolved.In this review,we considered recent advances in MEA probe-based wireless CL-DBS microsystems and outlined the major issues and promising prospects in this field.This technology has the potential to offer novel therapeutic options for psychiatric disorders in the future.

Humans ; Proto-Oncogene Proteins p21(ras)/genetics* ; Prognosis ; Biomarkers, Tumor/genetics* ; Mutation/genetics* ; Colorectal Neoplasms/genetics* ; Proto-Oncogene Proteins B-raf/metabolism*